Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab in high-risk COPD with eosinophilia
CTR20210176Phase 3Completed
- Sponsor
- GSK
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of mepolizumab in chronic obstructive pulmonary disease (COPD), sponsored by GSK. Started Feb 2021; status: completed.
02
Drugs
mepolizumab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20210176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210176.